The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
CMTM6
Copy number
PD-L1
Prognosis
Undifferentiated pleomorphic sarcoma
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
23
01
2021
accepted:
23
03
2021
pubmed:
4
4
2021
medline:
8
6
2021
entrez:
3
4
2021
Statut:
ppublish
Résumé
Undifferentiated pleomorphic sarcoma (UPS) is a sarcoma with a poor prognosis. A clinical trial, SARC028, revealed that treatment with anti-PD-1 drugs was effective against UPS. Studies have reported that UPS expresses PD-L1, sometimes strongly (≥ 50%). However, the mechanism of PD-L1 expression in UPS has remained unclear. CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) was identified as a novel regulator of PD-L1 expression. The positive relationship between PD-L1 and CMTM6 has been reported in several studies. The aim of this study was thus to examine CMTM6 expression in UPS and evaluate the relationship between PD-L1 and CMTM6 in this disease. Fifty-one primary UPS samples were subjected to CMTM6 and PD-L1 immunostaining. CMTM6 expression was assessed using proportion and intensity scores. CMTM6 gene copy number was also evaluated using a real-time PCR-based copy number assay. We also analyzed the mRNA expression and copy number variation of PD-L1 and CMTM6 in The Cancer Genome Atlas (TCGA) data. TCGA data indicated that the mRNAs encoded by genes located around 3p22 were coexpressed with CMTM6 mRNA in UPS. Both proportion and intensity scores of CMTM6 positively correlated with strong PD-L1 expression (≥ 50%) (both p = 0.023). CMTM6 copy number gain increased CMTM6 expression. Patients with UPS with a high CMTM6 intensity score had a worse prognosis for overall survival. UPS showed variation in CMTM6 copy number and CMTM6 expression. CMTM6 expression was significantly correlated with PD-L1 expression, especially with strong PD-L1 expression.
Sections du résumé
BACKGROUND
BACKGROUND
Undifferentiated pleomorphic sarcoma (UPS) is a sarcoma with a poor prognosis. A clinical trial, SARC028, revealed that treatment with anti-PD-1 drugs was effective against UPS. Studies have reported that UPS expresses PD-L1, sometimes strongly (≥ 50%). However, the mechanism of PD-L1 expression in UPS has remained unclear. CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) was identified as a novel regulator of PD-L1 expression. The positive relationship between PD-L1 and CMTM6 has been reported in several studies. The aim of this study was thus to examine CMTM6 expression in UPS and evaluate the relationship between PD-L1 and CMTM6 in this disease.
MATERIALS AND METHODS
METHODS
Fifty-one primary UPS samples were subjected to CMTM6 and PD-L1 immunostaining. CMTM6 expression was assessed using proportion and intensity scores. CMTM6 gene copy number was also evaluated using a real-time PCR-based copy number assay. We also analyzed the mRNA expression and copy number variation of PD-L1 and CMTM6 in The Cancer Genome Atlas (TCGA) data.
RESULTS
RESULTS
TCGA data indicated that the mRNAs encoded by genes located around 3p22 were coexpressed with CMTM6 mRNA in UPS. Both proportion and intensity scores of CMTM6 positively correlated with strong PD-L1 expression (≥ 50%) (both p = 0.023). CMTM6 copy number gain increased CMTM6 expression. Patients with UPS with a high CMTM6 intensity score had a worse prognosis for overall survival.
CONCLUSIONS
CONCLUSIONS
UPS showed variation in CMTM6 copy number and CMTM6 expression. CMTM6 expression was significantly correlated with PD-L1 expression, especially with strong PD-L1 expression.
Identifiants
pubmed: 33811537
doi: 10.1007/s00432-021-03616-4
pii: 10.1007/s00432-021-03616-4
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
CMTM6 protein, human
0
MARVEL Domain-Containing Proteins
0
Myelin Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2003-2011Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19H03444
Références
Boxberg M, Steiger K, Lenze U et al (2018) PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue—prognostic implications and rationale for immunotherapy. Oncoimmunology 7:1–11. https://doi.org/10.1080/2162402X.2017.1389366
doi: 10.1080/2162402X.2017.1389366
Burr ML, Sparbier CE, Chan Y-C et al (2017) CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549:101–105. https://doi.org/10.1038/nature23643
doi: 10.1038/nature23643
pubmed: 28813417
pmcid: 5706633
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (2013) WHO classification of tumours of soft tissue and bone. IARC Press, Lyon
Cerami et al (2017) The CBio cancer genomics. Cancer Discov 32:736–740. https://doi.org/10.1158/2159-8290.CD-12-0095
doi: 10.1158/2159-8290.CD-12-0095
Gao J, Aksoy BA, Dogrusoz U et al (2014) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal complementary data sources and analysis options. Sci Signal 6:1–20. https://doi.org/10.1126/scisignal.2004088
doi: 10.1126/scisignal.2004088
Ishihara S, Yamada Y, Iwasaki T et al (2020) PD-L1 and IDO-1 expression in undifferentiated pleomorphic sarcoma: the associations with tumor infiltrating lymphocytes, dMMR and HLA class I. Oncol Rep. https://doi.org/10.3892/or.2020.7837
doi: 10.3892/or.2020.7837
pubmed: 33155664
Keung EZ, Burgess M, Salazar R et al (2020) Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res 26:1258–1266. https://doi.org/10.1158/1078-0432.CCR-19-1824
doi: 10.1158/1078-0432.CCR-19-1824
pubmed: 31900276
pmcid: 7731262
Koh YW, Han JH, Haam S et al (2019) Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Oncoimmunology 8:1–7. https://doi.org/10.1080/2162402X.2019.1629261
doi: 10.1080/2162402X.2019.1629261
Li X, Chen L, Gu C et al (2020) CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ 8:1–13. https://doi.org/10.7717/peerj.9536
doi: 10.7717/peerj.9536
Liu LL, Zhang SW, Chao X et al (2020) Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-020-02691-9
doi: 10.1007/s00262-020-02691-9
pubmed: 33123754
pmcid: 7979613
Martinez-Morilla S, Zugazagoitia J, Wong PF et al (2020) Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology 10:1864909. https://doi.org/10.1080/2162402X.2020.1864909
doi: 10.1080/2162402X.2020.1864909
pubmed: 33457084
pmcid: 7781756
Mezzadra R, Sun C, Jae LT et al (2017) Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549:106–110. https://doi.org/10.1038/nature23669
doi: 10.1038/nature23669
pubmed: 28813410
pmcid: 6333292
Schalper KA, Carvajal-Hausdorf D, McLaughlin J et al (2017) Differential expression and significance of PD-L1, IDO-1, and B7–H4 in human lung cancer. Clin Cancer Res 23:370–378. https://doi.org/10.1158/1078-0432.CCR-16-0150
doi: 10.1158/1078-0432.CCR-16-0150
pubmed: 27440266
Tawbi HA, Burgess M, Bolejack V et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493–1501. https://doi.org/10.1016/S1470-2045(17)30624-1
doi: 10.1016/S1470-2045(17)30624-1
pubmed: 28988646
pmcid: 7939029
WHO Classification of Tumours Editorial Board (2020) Soft tissue and bone tumours. International Agency for Research on Cancer, Lyon (France). https://publications.iarc.fr/588
Zugazagoitia J, Liu Y, Toki M et al (2019) Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small cell lung cancer. J Thorac Oncol 14:2084–2096. https://doi.org/10.1016/j.jtho.2019.09.014
doi: 10.1016/j.jtho.2019.09.014
pubmed: 31605795
pmcid: 6951804